Aclaris Therapeutics, Inc. SEC filings ACRS
Aclaris Therapeutics, Inc. has 872 filings in SEC EDGAR's recent list, going back to Sep 10, 2012. Its latest annual report, Form ARS, was filed on Apr 23, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 424B5 | Prospectus supplement | Oct 27, 2026 | — |
| S-3ASR | Automatic shelf registration | Aug 6, 2026 | — |
| S-8 | Employee stock plan registration | Jun 5, 2025 | — |
| S-3 | Shelf registration | Feb 27, 2025 | — |
| 424B3 | Prospectus | Dec 31, 2024 | — |
| S-3 | Shelf registration | Dec 19, 2024 | — |
| S-8 | Employee stock plan registration | Nov 27, 2024 | — |
| S-8 | Employee stock plan registration | May 7, 2024 | — |
| S-8 | Employee stock plan registration | May 8, 2023 | — |
| 424B5 | Prospectus supplement | Feb 23, 2023 | — |
| S-8 | Employee stock plan registration | May 10, 2022 | — |
| 424B5 | Prospectus supplement | Jun 10, 2021 | — |
| 424B5 | Prospectus supplement | Jun 8, 2021 | — |
| S-3ASR | Automatic shelf registration | May 20, 2021 | — |
| S-8 | Employee stock plan registration | May 7, 2021 | — |
| 424B5 | Prospectus supplement | Jan 20, 2021 | — |
| S-3MEF | Filing | Jan 20, 2021 | — |
| 424B5 | Prospectus supplement | Jan 19, 2021 | — |
| 424B5 | Prospectus supplement | Aug 13, 2020 | — |
| S-8 | Employee stock plan registration | May 7, 2020 | — |
| 424B5 | Prospectus supplement | Apr 29, 2020 | — |
| S-3 | Shelf registration | Mar 13, 2020 | — |
| S-8 | Employee stock plan registration | Mar 29, 2019 | — |
| 424B5 | Prospectus supplement | Oct 18, 2018 | — |
| S-3MEF | Filing | Oct 17, 2018 | — |
| 424B5 | Prospectus supplement | Oct 17, 2018 | — |
| S-8 | Employee stock plan registration | Mar 26, 2018 | — |
| S-8 | Employee stock plan registration | Aug 24, 2017 | — |
| 424B5 | Prospectus supplement | Aug 11, 2017 | — |
| 424B5 | Prospectus supplement | Aug 9, 2017 | — |
| S-8 | Employee stock plan registration | Mar 15, 2017 | — |
| POS AM | Filing | Nov 28, 2016 | — |
| 424B3 | Prospectus | Nov 18, 2016 | — |
| 424B5 | Prospectus supplement | Nov 18, 2016 | — |
| 424B5 | Prospectus supplement | Nov 17, 2016 | — |
| 424B3 | Prospectus | Nov 15, 2016 | — |
| 424B5 | Prospectus supplement | Nov 14, 2016 | — |
| 424B3 | Prospectus | Nov 3, 2016 | — |
| S-3 | Shelf registration | Nov 2, 2016 | — |
| 424B3 | Prospectus | Nov 2, 2016 | — |
| 424B3 | Prospectus | Sep 13, 2016 | — |
| 424B3 | Prospectus | Aug 11, 2016 | — |
| 424B3 | Prospectus | Aug 4, 2016 | — |
| 424B3 | Prospectus | Jun 29, 2016 | — |
| 424B4 | Prospectus | Jun 28, 2016 | — |
| S-1 | Registration statement | Jun 17, 2016 | — |
| S-8 | Employee stock plan registration | Mar 24, 2016 | — |
| S-8 | Employee stock plan registration | Oct 15, 2015 | — |
| 424B4 | Prospectus | Oct 8, 2015 | — |
| S-1/A | Amended registration statement | Oct 1, 2015 | — |
| S-1/A | Amended registration statement | Sep 25, 2015 | — |
| S-1/A | Amended registration statement | Sep 4, 2015 | — |
| S-1 | Registration statement | Aug 17, 2015 | — |
Showing 53 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ACRS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Wayne, PA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1557746
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.